Rimtoregtide is under clinical development by HighTide Therapeutics and currently in Phase I for Cytokine Release Syndrome (Cytokine Storm). According to GlobalData, Phase I drugs for Cytokine Release Syndrome (Cytokine Storm) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Rimtoregtide LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Rimtoregtide is under development for the treatment of acute pancreatitis, alcoholic hepatitis and cytokine release syndrome. It is administered through parenteral route as a solution. The therapeutic candidate is a 15-amino acid long synthetic peptide analog of RegIII/PAP protein. It was under development for the treatment of type 2 diabetes and for beta cell regeneration or islet transplantation
HighTide Therapeutics overview
HighTide Therapeutics., is a biopharmaceutical company focused on discovering and developing novel drugs to treat chronic liver diseases, gastrointestinal diseases and metabolic disorders. The company is headquartered in China.
For a complete picture of Rimtoregtide’s drug-specific PTSR and LoA scores, buy the report here.